ConductScience.org, home
Papers
API referenceFor AI assistants

Paper · 25678581

Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma.

Winograd R and 10 others. Cancer Immunol Res, 2015. Cited by 386 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma. Papers, record 25678581. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/25678581

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma.
PubMed
Journal
Cancer Immunol Res
PubMed
Year
2015
PubMed
Publication types
Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
386
iCite
Relative citation ratio, by iCite
10.2
iCite
Revised in PubMed
2024-01-02
PubMed

Authors11

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Winograd RRafael
2Byrne KTKatelyn T
3Evans RARebecca A
4Odorizzi PMPamela M
5Meyer ARAnders R L
6Bajor DLDavid L
7Clendenin CCynthia
8Stanger BZBen Z
9Furth EEEmma E
10Wherry EJE John

1 to 10 of 11Source PubMed

See all 11 authors

Topics23

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
B7-H1 AntigenMajor topic
CTLA-4 AntigenMajor topic
Carcinoma, Pancreatic DuctalMajor topic
Pancreatic NeoplasmsMajor topic
T-Lymphocyte SubsetsMajor topic
Animals
Antibodies, Monoclonal
Antimetabolites, Antineoplastic
CD40 Antigens
Cell Line, Tumor
Combined Modality Therapy
Deoxycytidine
Female
Genetic Engineering
Humans
Immune Tolerance
Immunity, Cellular
Interferon-gamma
Lymphocyte Activation
Mice, Inbred C57BL
Tumor Microenvironment
Xenograft Model Antitumor Assays
Gemcitabine

Source PubMed

Grants8

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
T32 HL007439NHLBI NIH HHSUnited StatesT32HL007439PubMed and NIHNIH RePORTER
T32 CA009140NCI NIH HHSUnited StatesT32CA009140PubMed and NIHNIH RePORTER
U19 AI082630NIAID NIH HHSUnited StatesU19AI082630PubMed and NIHNIH RePORTER
P01 AI112521NIAID NIH HHSUnited StatesP01AI112521PubMed and NIHNIH RePORTER
R01 CA169123NCI NIH HHSUnited StatesR01CA169123PubMed and NIHNIH RePORTER
P30 CA016520NCI NIH HHSUnited StatesP30CA016520PubMed and NIHNIH RePORTER
T32 HL007775NHLBI NIH HHSUnited StatesT32HL007775PubMed and NIHNIH RePORTER
U19 AI 082630NIAID NIH HHSUnited StatesU19AI082630PubMed and NIHNIH RePORTER

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References80

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
125,428,504Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.Nature2014https://conductscience.org/library/papers/25428504PubMed
223,197,535Progenitor and terminal subsets of CD8+ T cells cooperate to contain chronic viral infection.Science2012https://conductscience.org/library/papers/23197535PubMed
324,589,924Immune cell-poor melanomas benefit from PD-1 blockade after targeted type I IFN activation.Cancer Discov2014https://conductscience.org/library/papers/24589924PubMed
423,724,867Nivolumab plus ipilimumab in advanced melanoma.N Engl J Med2013https://conductscience.org/library/papers/23724867PubMed
524,777,248Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells.Cancer Immunol Res2013https://conductscience.org/library/papers/24777248PubMed
620,160,101PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors.Proc Natl Acad Sci U S A2010https://conductscience.org/library/papers/20160101PubMed
724,598,590Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy.Sci Transl Med2014https://conductscience.org/library/papers/24598590PubMed
817,909,062Dynamics of the immune reaction to pancreatic cancer from inception to invasion.Cancer Res2007https://conductscience.org/library/papers/17909062PubMed
919,013,709Immunosurveillance of pancreatic adenocarcinoma: insights from genetically engineered mouse models of cancer.Cancer Lett2009https://conductscience.org/library/papers/19013709PubMed
1023,649,004Immunomodulatory monoclonal antibodies combined with peptide vaccination provide potent immunotherapy in an aggressive murine neuroblastoma model.Clin Cancer Res2013https://conductscience.org/library/papers/23649004PubMed

1 to 10 of 80

See all 80 references

Cited by301

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 386 citations.

PMIDTitleJournalYearIn PapersSource
42,824,772Targeting VISTA as a novel immunotherapy for skin cancer.Front Immunol2026https://conductscience.org/library/papers/42824772PubMed
42,784,801IFNγ-dependent tumor-cell MHC-II is restrained by MAPK signaling and associated with immunotherapy responsiveness in pancreatic ductal adenocarcinoma.Cancer Immunol Res2026https://conductscience.org/library/papers/42784801PubMed
42,649,211Oncogenic Kras targeting with MRTX1133 or Daraxonrasib specifically synergize with anti-CTLA4 to promote anti-tumor immunity in pancreatic cancer.Nat Commun2026https://conductscience.org/library/papers/42649211PubMed
42,499,227CD40 Agonist Therapy in Melanoma: Translating Preclinical Promise Into Clinical Practice.Pigment Cell Melanoma Res2026https://conductscience.org/library/papers/42499227PubMed
42,279,326CD40 Agonism in Pancreatic Ductal Adenocarcinoma: Expression, Biology, and Therapeutic Targeting.Cancers (Basel)2026https://conductscience.org/library/papers/42279326PubMed
42,192,927The Differential Impact of Neoadjuvant Therapies on the Tumor Microenvironment, Peripheral Biomarkers, and Survival in Pancreatic Cancer: A Retrospective Cohort Study.Cancers (Basel)2026https://conductscience.org/library/papers/42192927PubMed
42,027,643Hypoxia-inducible factors: Regulatory functions and status as a therapeutic target in gastric cancer (Review).Oncol Lett2026https://conductscience.org/library/papers/42027643PubMed
41,932,343Agonistic anti-CD40 antibody treatment converts resident regulatory T cells into activated type 1 effectors within the tumor microenvironment.Immunity2026https://conductscience.org/library/papers/41932343PubMed
41,919,662The 15-year bibliometric landscape of glioblastoma vaccines: Emergence of combinatorial immunotherapy.Hum Vaccin Immunother2026https://conductscience.org/library/papers/41919662PubMed
41,850,678Interleukin 6 Drives Durable T Cell-Mediated Immunity to Pancreatic Cancer.Cell Mol Gastroenterol Hepatol2026https://conductscience.org/library/papers/41850678PubMed

1 to 10 of 301

See all 301 cited by

Genes11

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
ALB213PubTator's text mininghttps://conductscience.org/library/genes/213NCBI Gene
CD27429,126PubTator's text mininghttps://conductscience.org/library/genes/29126NCBI Gene
CD4920PubTator's text mininghttps://conductscience.org/library/genes/920NCBI Gene
CD8A925PubTator's text mininghttps://conductscience.org/library/genes/925NCBI Gene
CTLA41,493PubTator's text mininghttps://conductscience.org/library/genes/1493NCBI Gene
EGFR1,956PubTator's text mininghttps://conductscience.org/library/genes/1956NCBI Gene
IFNG3,458PubTator's text mininghttps://conductscience.org/library/genes/3458NCBI Gene
LAG33,902PubTator's text mininghttps://conductscience.org/library/genes/3902NCBI Gene
PDCD1LG280,380PubTator's text mininghttps://conductscience.org/library/genes/80380NCBI Gene
PDX13,651PubTator's text mininghttps://conductscience.org/library/genes/3651NCBI Gene

1 to 10 of 11

See all 11 genes

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/25678581

GET https://conductscience.org/api/papers/v1/25678581/references?page=2

API referenceFor AI assistants